Elysium Health Expands Access to New Peptides Under Updated HHS Policy

Elysium Health™ Enhances Peptide Access Under New HHS Policy

Elysium Health, Inc.™, a frontrunner in longevity science, has recently unveiled its intention to expand the availability of six additional peptides through Elysium Health Rx™. This initiative is a direct response to a new interim enforcement-discretion policy from the U.S. Department of Health and Human Services (HHS). The announcement also includes the launch of the Elysium Peptide Evidence and Evaluation Resource (PEER) to further propel peptide research.

The decision follows Elysium's active participation in the Food and Drug Administration (FDA)'s Pharmacy Compounding Advisory Committee meeting held in July, where the company advocated for broader peptide accessibility alongside enhanced safety and manufacturing standards. This new HHS policy aligns with several recommendations made by Elysium, paving the way for the limited compounding of compounds such as BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. These compounds are subject to stringent guidelines, including manufacturer qualifications, rigorous product testing, patient-specific prescriptions, and adverse-event reporting, all aimed at ensuring increased patient safety and product quality.

Since its inception in 2015, Elysium Health has been at the forefront of translating cutting-edge research in aging into scientifically validated products, conducting over 25 clinical trials, and establishing robust partnerships with reputable research institutions. With the demand for peptides growing rapidly, Elysium’s approach is built on a solid foundation of scientific expertise and a commitment to quality, ideally positioning the company in this flourishing market.

Elysium co-founder and CEO, Eric Marcotulli, expressed encouragement regarding HHS's actions, remarking that the advancement of patient access must not compromise safety. He noted the increasing popularity of these peptides among consumers and highlighted the risks posed by unregulated suppliers. To combat these challenges, Elysium aims to set a benchmark for the marketplace that prioritizes medically-supervised alternatives,
verified ingredients, and proper dosing while simultaneously accelerating the necessary scientific investigations.

The peptide program will be guided by leading scientists and clinicians specializing in the six peptides included in the HHS policy. This initiative mirrors Elysium's prestigious Scientific Advisory Board, convening experts to analyze emerging evidence, direct scientific strategies, and set research priorities in collaboration with internal scientific teams and institutional research partners. This blend of scientific guidance, stringent quality standards, and personalized clinical support is set to define Elysium's novel approach to peptide therapies.

To ensure that broader access is supported by strong scientific backing, Elysium is rolling out PEER to facilitate access to high-quality, rigorously characterized peptides for universities, hospitals, non-profits, and other qualifying research institutions. This program aims to close the existing gap between rising consumer interest and the paucity of human clinical evidence regarding these peptides, all under the stewardship of leading experts.

Elysium is also embarking on an innovative research project, TIME-PEP, designed to study the epigenetic effects of peptide usage and its correlation with biological aging, morbidity, and mortality. Conducted through Elysium's Aging Research Center (ARC), this pioneering endeavor offers consumers the chance to participate directly in research on longevity, contributing to a broader epigenetic database.

Dr. Leonard Guarente, Elysium’s co-founder and chief scientist, emphasized the potential of peptides in advancing longevity science. Reflecting on Elysium's prior successes in establishing high standards for product quality and rigorous clinical research in other areas of health, he affirmed the company’s readiness to extend that commitment to the realm of peptides.

As Elysium prepares to launch these six new peptides under Elysium Health Rx by year's end, the offerings will be subject to existing regulations and individualized evaluations by board-certified physicians. Interested individuals can find further information on availability at elysiumhealthrx.com/peptides-waitlist.

Despite this progress, it's crucial to note that the recent HHS policy does not equate to FDA approval for the listed peptides, and compounded drugs do not undergo the FDA's safety or effectiveness scrutiny. The medical services provided via Elysium Health Rx are carried out by independent board-certified physicians, with the availability of prescriptions and treatments guided by clinical evaluations.

In conclusion, Elysium Health's aggressive stance on expanding peptide accessibility and emphasizing scientific rigor represents a significant leap in the integration of longevity research into practical health solutions aimed at enhancing the well-being of individuals today. With the backing of notable investors and ongoing partnerships with leading scientists, Elysium Health stands poised to redefine health solutions for an aging population.